^
    Back
    Association details:
    Biomarker:KRAS mutation
    Cancer:Melanoma
    Drug:Mekinist (trametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Open-label Study to Investigate the Safety, PK, and Pharmacodynamics of GSK1120212 in Subjects With Solid Tumors or Lymphoma

    Excerpt:
    ...- CRC must be KRAS or BRAF mutation positive....
    Trial ID:
    NCT00687622
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Mol Cancer Ther
    Title:

    Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors

    Excerpt:
    Strikingly, we observed that some of the cell lines that exhibited resistance to the single agents but were synergistically inhibited by the combination also had an activating mutation in either KRAS (SW480, SW837, DLD1, HCT116, HCT15) or loss-of-function mutations in NF1 (LOXIMVI, HCT116, RKO, MeWo; Fig. 5A; ref. 24).
    DOI:
    10.1158/1535-7163.MCT-15-0136-T